Sanara MedTech Inc.

NASDAQ:SMTI

Medical - Instruments & Supplies

Healthcare
$32.73 +3.44%

+$0.73 today

Market cap
$300.55M
Beta
1.19
P/E (TTM)
-5.7
EPS (TTM)
-$3.86
52W Low $16.05High $35.95

Volume 0.07M

Average 0.06M

SMTI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Sanara MedTech Inc.NASDAQ: SMTI

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.03M fell 21.2% year over year, ahead of the -91.0% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -35.7% a year.

Context

  • Stock-based compensation amounted to 0.7% of revenue in FY2025, down 4.4 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -21.2% holds above the trailing-twelve-month pace of -91.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.03M+150.9% QoQ
Last fiscal yearDec 2025
$718.71K-83.8% YoY
LTMMar 2026
$442.14K-91.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.2%——
1 year-83.8%——
3-year CAGR-35.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
718.71K USD
Year-over-year change
-83.8%
4-year CAGR
-28.0%

Stock-Based Compensation vs competitors

How SMTI compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -91.0% is the lowest of 10, against a peer median of -7.7%.
  • Stock-based compensation amounts to 0.4% of revenue for SMTI, versus a peer median of 3.7%.
SMTI Competitors
Stock-Based Compensation for SMTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NEONeoGenomics, Inc.LTM Jun 2026$28.16M USD-29.2%+18.8%3.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$19.27M USD-0.0%+25.6%335.8%
TBRGTruBridge, Inc.LTM Mar 2026$17.06M USD+187.5%+18.7%4.9%
SGHTSight Sciences, Inc.LTM Mar 2026$11.67M USD-30.6%+0.2%14.7%
STXSStereotaxis, Inc.LTM Mar 2026$9.43M USD-7.7%-2.3%30.2%
VMDViemed Healthcare, Inc.LTM Mar 2026$9.27M USD+29.4%+20.6%3.2%
LFMDLifeMD, Inc.LTM Mar 2026$7.95M USD-35.1%-8.6%3.6%
XGNExagen Inc.LTM Mar 2026$2.4M USD+47.3%-22.9%3.5%
HITIHigh Tide Inc.LTM Apr 2026CA$1.86M CAD-54.1%-21.4%0.3%
SMTISanara MedTech Inc.LTM Mar 2026$442.14K USD-91.0%-35.7%0.4%
Peer median (excluding SMTI) —-7.7%+0.2%3.7%

Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.99M)(8.09M)(4.44M)(9.91M)(27.66M)
Depreciation & Amortization596.98K2.37M3.68M4.92M28.56M
Deferred Income Tax0(5.84M)000
Stock-Based Compensation2.67M2.7M3.44M4.44M718.71K
Change in Working Capital(1.18M)517.62K(3.28M)(911.72K)(3.84M)
Accounts Receivables(774.81K)(2.27M)(1.73M)(4.54M)4.03M
Inventory(1.15M)(517.27K)(1.55M)1.44M(431.33K)
Accounts Payables99.13K(423.75K)575.15K(471.21K)1.24M
Other Working Capital645.56K3.73M(577.32K)2.66M(8.68M)
Other Non-Cash Items1.1M2.79M(2.64M)1.44M9.02M
Operating Cash Flow(4.81M)(5.55M)(3.25M)(23.78K)6.79M
Capital Expenditures(750.45K)(747.02K)(265.25K)(229.3K)(4.63M)
Acquisitions (Net)0(2.52M)(9.94M)00
Purchases of Investments(4.53M)(250K)0(5.3M)9.48M
Sales of Investments0000(2.96M)
Other Investing Activities(578.59K)(598.45K)650(1.1M)(10.47M)
Investing Cash Flow(5.28M)(3.51M)(10.21M)(6.61M)(8.36M)
Debt Repayment009.69M19.59M0
Common Stock Issued28.94M0911.37K00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(642.53K)(627.35K)(958.59K)(2.15M)(8.48M)
Financing Cash Flow28.3M(627.35K)9.64M17.37M(8.48M)
Effect of Forex Changes00000
Net Change in Cash18.2M(9.69M)(3.81M)10.73M(10.03M)
Free Cash Flow(5.56M)(6.3M)(3.51M)(253.08K)2.16M

Sanara MedTech Inc.

NASDAQ:SMTI

Intrinsic Alpha fair value

Locked

Current Price

$32.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.